Synklino

Synklino is an emerging biotechnology company developing breakthrough drugs for the treatment of chronic viral infections. Synklino will advance its candidate drug SYN002 for the treatment of cytomegalovirus (CMV) into ex vivo and in vivo Phase 1 clinical trials, generating safety and efficacy data to lay a solid foundation for expanding the company’s product pipeline and broadening strategic options for further value creation.